Vericel (VCEL) EBITDA (2010 - 2026)
Vericel recorded quarterly EBITDA of -$8.1 million in Q1 2026, down 135.98% quarter-over-quarter from $22.4 million in Q4 2025, and up 36.96% year-over-year from -$5.9 million in Q1 2025.
Vericel's EBITDA history runs 17 years deep, the most recent figure standing at -$8.1 million for Q1 2026.
- In Q1 2026, EBITDA rose 36.96% year-over-year to -$8.1 million; the TTM figure through Mar 2026 stood at $15.8 million (up 661.48% YoY), while the FY2025 annual figure was $11.0 million, up 144.39% from the prior year.
- EBITDA came in at -$8.1 million for Q1 2026 at Vericel, down from $22.4 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of $22.4 million in Q4 2025 to a low of -$12.8 million in Q1 2025.
- A 5-year average of -$942529.4 and a median of -$5.5 million in 2024 frame the typical range for EBITDA.
- Across the five-year window, EBITDA slumped 143.55% in 2022 and surged 239.96% in 2025, its largest moves.
- Vericel's EBITDA stood at $6.1 million in 2022, then jumped by 109.22% to $12.7 million in 2023, then surged by 45.15% to $18.5 million in 2024, then increased by 21.3% to $22.4 million in 2025, then slumped by 135.98% to -$8.1 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$8.1 million, $22.4 million, and $3.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Vericel | 1.69 Bn | 1.55 Bn | 49.27 Mn | -8.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.06 Mn |
| Dec 31, 2025 | 22.42 Mn |
| Sep 30, 2025 | 3.45 Mn |
| Jun 30, 2025 | -2.03 Mn |
| Mar 31, 2025 | -12.79 Mn |
| Dec 31, 2024 | 18.48 Mn |
| Sep 30, 2024 | -2.47 Mn |
| Jun 30, 2024 | -6.03 Mn |
| Mar 31, 2024 | -5.46 Mn |
| Dec 31, 2023 | 12.73 Mn |
| Sep 30, 2023 | -5.06 Mn |
| Jun 30, 2023 | -5.96 Mn |
| Mar 31, 2023 | -8.18 Mn |
| Dec 31, 2022 | 6.09 Mn |
| Sep 30, 2022 | -6.79 Mn |
| Jun 30, 2022 | -9.08 Mn |
| Mar 31, 2022 | -7.27 Mn |
| Dec 31, 2021 | 4.14 Mn |
| Sep 30, 2021 | -4.96 Mn |
| Jun 30, 2021 | -3.73 Mn |
| Mar 31, 2021 | -3.31 Mn |
| Dec 31, 2020 | 12.29 Mn |
| Sep 30, 2020 | 3.52 Mn |
| Jun 30, 2020 | -8.36 Mn |
| Mar 31, 2020 | -5.08 Mn |
| Dec 31, 2019 | 9.21 Mn |
| Sep 30, 2019 | 3.10 Mn |
| Jun 30, 2019 | -20.20 Mn |
| Mar 31, 2019 | -3.36 Mn |
| Dec 31, 2018 | 6.00 Mn |
| Sep 30, 2018 | -1.34 Mn |
| Jun 30, 2018 | -4.25 Mn |
| Mar 31, 2018 | -4.32 Mn |
| Dec 31, 2017 | 1.19 Mn |
| Sep 30, 2017 | -4.03 Mn |
| Jun 30, 2017 | -2.52 Mn |
| Mar 31, 2017 | -9.62 Mn |
| Dec 31, 2016 | 1.19 Mn |
| Sep 30, 2016 | -6.38 Mn |
| Jun 30, 2016 | -4.98 Mn |
| Mar 31, 2016 | -1.99 Mn |
| Dec 31, 2015 | -4.96 Mn |
| Sep 30, 2015 | -4.88 Mn |
| Jun 30, 2015 | -2.27 Mn |
| Mar 31, 2015 | -2.15 Mn |
| Dec 31, 2014 | -2.35 Mn |
| Sep 30, 2014 | -8.02 Mn |
| Jun 30, 2014 | -8.52 Mn |
| Mar 31, 2014 | -4.65 Mn |
| Dec 31, 2013 | -4.92 Mn |
| Sep 30, 2013 | -3.64 Mn |
| Jun 30, 2013 | -5.23 Mn |
| Mar 31, 2013 | -7.17 Mn |
| Dec 31, 2012 | -7.62 Mn |
| Sep 30, 2012 | -8.29 Mn |
| Jun 30, 2012 | -9.30 Mn |
| Mar 31, 2012 | -8.56 Mn |
| Dec 31, 2011 | -7.83 Mn |
| Sep 30, 2011 | -7.44 Mn |
| Mar 31, 2011 | -6.26 Mn |
| Sep 30, 2010 | -5.85 Mn |
| Jun 30, 2010 | -5.14 Mn |